Shengshi (Beijing) Bioengineering Co., Ltd.

SCLnow?Shengshi? was founded in 2011 and is a Chinese multinational enterprise dedicated to the combination of stem cell translational medicine and regenerative medicine across the entire industry chain. Shengshi owns the world's largest stem cell life energy bank, storing "Shengbao'er" (umbilical cord multipotent stem cells), which are new life energy sources defined by international standards (ISO/TC276), and are irreplaceable life energy seeds for future precision and personalized treatments. At the same time, Shengshi is also the developer of international, national, and industry standards for umbilical cord multipotent stem cells. Domestically, it holds honors such as National High-tech Enterprise, Zhongguancun High-tech Enterprise, China Industry-University-Research Cooperative Innovation Demonstration Base, and Chairman Unit of the China Stem Cell Translational Medicine Standards Industry-University-Research Alliance. Internationally, it is a member of the American National Standards Institute-American Society for Quality (ANAB), a member of the International Society for Stem Cell Research (ISSCR), a member of the International Society for Cell Therapy (ISCT), and a co-convener of ISO/TC276 International Biotechnology Standards Committee.
SCLnow?Shengshi?'s research team is a world-class scientific research team that has repeatedly represented China in formulating ISO/TC276 international standards for stem cells, and has applied for multiple patents related to clinical-grade stem cell isolation, culture, differentiation induction, and more. Currently, the team is dedicating more efforts to the translation of stem cell achievements and regenerative medicine, achieving clinical standardized transformation in areas such as stem cell application in disease treatment, tissue engineering, organ reconstruction, and personalized precision medicine.
SCLnow?Shengshi? has established branch companies in multiple provinces, cities, and overseas, with business covering more than 20 major provinces and cities nationwide. It collaborates with top-tier Grade III Class A hospitals such as Peking University Third Hospital, Hunan Xiangya Hospital, and Beijing Obstetrics and Gynecology Hospital to carry out dozens of stem cell clinical projects.